sulfinpyrazone has been researched along with Hyperlipoproteinemia Type II in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sommariva, D | 1 |
| Scotti, L | 1 |
| Baroni, L | 1 |
| Beggi, P | 1 |
| Fasoli, A | 1 |
1 other study available for sulfinpyrazone and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
[Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
Topics: Adult; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipi | 1980 |